UNDERVALUED PENNY STOCKS

[ORCA]

NEOT.494.HUGE ALERT.A NASDAQ PHARMA CO.WAS $2.52 IN MAY.BOOK VALUE $1.36.May 30 2017 2.5199999 2.4932 -0.01 -0.27% 2.48 2.5352001 30,386
CHECK DD BELOW.THIS THING WILL SEE A MINIMUM $1.36 BOOK VALUE PRICE IMO.
HUGE CASH ON HAND.
As of April 28, 2017, the registrant had 13,831,747 shares of common stock
INSIDERS HAVE NOT SOLD SHARES SINCE 2015.
Total stockholders’ equity $9,035,445
Cash equivalentend of period $9,843,138
Ownership Summary as reported in the most recent 13F filings
http://www.nasdaq.com/symbol/neot/institutional-holdings/sold-out
Institutional Ownership 12.17%
Total Shares Outstanding (millions) 14
Total Value of Holdings (millions) $1

Active Positions

HOLDERS SHARES
Increased Positions 10 115,562
Decreased Positions 4 23,334
Held Positions 5 1,544,836
Total Institutional Shares 19 1,683,732
New and Sold Out Positions
Total ActiveShares
New/SoldShares
0k
100k
-100k
200k
HOLDERS SHARES
New Positions 6 76,567
Sold Out Positions 1 18,300
SAN DIEGO, July 10, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) announced today that its Board of Directors has unanimously approved plans to initiate a process to explore and review a range of strategic alternatives focusing on seeking an acquisition, business combination or partnership that will allow for it to maximize shareholder value from its remaining assets and cash resources. Neothetics has engaged Oppenheimer and Co., Inc. to act as its exclusive financial advisor to the company and Board for this process. The Company also intends to streamline its operations in order to preserve its capital and cash resources, including implementing a reduction in workforce.

“We have unanimously determined that seeking a strategic transaction gives us the best opportunity to maximize shareholder value,” said Kim Kamdar, Ph.D., a member of Neothetics’ Operating Committee and Board of Directors. “In addition, we continue to review all operational expenses in order to facilitate our ability to enter into a strategic transaction.